

127, 17 27, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20) 77, 17 (20









جامعة عين شمس

التوثيق الالكتروني والميكروفيلم



نقسم بللله العظيم أن المادة التي تم توثيقها وتسجيلها علي هذه الأفلام قد اعدت دون آية تغيرات



يجب أن

تحفظ هذه الأفلام بعيداً عن الغبار

في درجة حرارة من 15-20 مئوية ورطوبة نسبية من 20-40 %

To be kept away from dust in dry cool place of 15 – 25c and relative humidity 20-40 %



ثبكة المعلومات الجامعية





Information Netw. " Shams Children Sha شبكة المعلومات الجامعية @ ASUNET بالرسالة صفحات لم ترد بالأص

Telomerase Activity in Normal Leukocytes and Hematological Malignancies

AN ESSAY

Submitted for Partial Fulfillment of the Master Degree in CLINICAL & CHEMICAL PATHOLOGY

By:

Hanan Abd El-Majeed Mohamed M.B., B.Ch.

Supervisors

Prof. Dr. Taghreed Mohamed Gaafar

Professor of Clinical and Chemical Pathology,
Faculty of Medicine,
Cairo University.

Dr. Shereen Mahmoud Shawky

Lecturer of Clinical and Chemical Pathology,

Faculty of Medicine,

Cairo University.

Faculty of Medicine Cairo University 2001

B1911

Acknowledgement

I wish to thank cordially and express supreme gratitude to Prof. Dr. Taghreed Mohamed Gaafar, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University for her kind supervision, continuous effort and constant encouragement to me in this work.

I would like to express my deep appreciation and profound gratitude to Dr. Shereen Mahmoud Shawky, Lecturer of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University for her kind assistance and continuous guidance throughout the conduction of this work.

Charles Charles & Tool Charles Commenter of the Commenter

(esta .

لجنة الحكم على الرسيسالة المقدسة مسيسين	اجتماع
ر مام عد المروع عي	الطهيم
للحسول على درجية الباجستير / آلة أتنسسواة	توطئة ا
الما درار ما المكان كم والله ما يك	في ـــــ
elemenouse activity in normal lenkocytes	تعفوان ؛ باللغة الانجليزية ؛ (
elemerose activity in normal lenkocyter and hemotological molignancies	·
من اط ان ع التيلوميون عن فلايا الم الطبيس. ورجانات الم	: باللغة المرسيسة
و الناف الم	
تاريخ ١٨ / ٨ / ١٩٠١ تم تشكيل لجنة الفحمى والبناقشة للرسسيا نب	ينام على موافقة السعة ي
:	تعوم المسلام على النصر نالي
<u> - عبار الماد المادلول كليكم - صالعة العدالة من المد رو</u>	20
دلقائدر هروردا اشارولوها الالمدكم طبالعظ العمالهم) مستحن واخل	reacel sit
<u> اوار (أ سالساليا كوها والأكارك عاد الأراع) مستحن خارج</u>	epder al
فردا وكتابة تقارير منفردة لكل منسهر إنماندت اللحنة مجتبعسة فيسبب	المحص أنوسا له بنواسطه كل عضورة
1 allo allo allo 26 10 / 10	<u> </u>
المناقشة الطالب في مقمل قمل عملا القبالية والقموس	· الطب جامعة القاهرة وذلك
عليها البحث ٠	ا وكذلك الاسسالملوية التي تام
	اللجنة :
4 4 (1) 2/2 /2/2 /2/2 /2/2 /2/2 /2/2	
بله الم البسيتر الم تعد ممالط به / (المعبد البيرية بيرية المركب	والم ارادا س
	سالکھا تے
	- ""-
	ترفيمات أعناه اللجنسة : ــ
المتحن الداخلس المتحن الخارجس	اليشوف المتحسن
المنتحن الداخلس المنتحن الخارجس	0.01.00

جامعة القاهرة / كلية الا القصر الديسستي



Abstract

The end of chromosome in higher eukaryote are termed telomere. Telomeric DNA consists of tandemly repeated DNA sequences which are gradually lost with age and with replication in vitro.

Telomerase is a specialized reverse transcriptase that catalyzes elongation of the telomeric tandem repeat, TTAGGG, by addition of this sequence to the

ends of existing telomeres.

Telomerase is expressed in embryonic cells and in adult germline cells, but it is undetectable in normal somatic cells except for proliferative cells of renewable tissues.

It has been discovered that there is an association between telomerase activity and cell proliferation because terminal differentiation is followed by down

regulation of telomerase activity.

Also, there are recent observations that cellular life-span can be extended by forced expression of telomerase, this might provide a route to delay some of

the aged related changes ascribable to replicative senescence.

The normal hemopoietic system harbors telomerase competent cells with the capacity to upregulate telomerase activity to a notable levels. High telomerase activity is found in progenitor stem cells and activated lymphocytes in vitro as well as in vivo, indicating that cells with high growth requirement can upregulate telomerase activity.

Also, telomerase activity can be detected in most primary human specimens and tumor derived cell lines. The activation of telomerase in malignant cancers seems to be an important step in tumorigenesis, whereby the cell gain the ability of indefinite proliferation and become immortal.

In malignant hematopoietic disorders telomerase activity is a general finding but with a different levels. The highest telomerase expression has been shown in acute leukemias and non-Hodgkin's lymphomas also the level of activity is parallel to tumor progression, also the mean TRF length may disclose how far the disease has progressed and may be a marker for disease severity.

Thus, it is becoming generally accepted that telomerase could be a reliable new marker for detection of cancers. Moreover, a novel therapy for tumor expression has been developed using telomerase inhibitors, with the hope that the lack of telomerase expression in normal somatic cells would results in highly specific treatment with fewer side effects than conventional chemotherapy

Key Word:

Ġ. Ò.

28 $U_{\widetilde{C}_{i}}$

53 ř.

(*

Contents

		age
*	Introduction and Aim of the Work	. 1
*	Telomeres	
	• Telomere ends	. 4
	Telomere loss and cellular senescence	. 8
*	Telomerase Enzyme and Normal Hematopoietic Cells	•
	Telomerase enzyme	12
	• Structure of telomerase	13
	Telomerase regulation	16
	• Telomerase as a gene therapy for ageing	18
	• Telomerase regulation and telomere stability in primitive	•
	hematopoietic cells	20
	• Telomerase activation during human B-cell	
	differentiation	24
	Telomerase expression in human T-cell development and	
	activation	27
*	Telomerase and Malignancy	
	• How might telomerase contribute to cancer?	31
	• Telomerase in early detection of cancer	34
	• Telomerase as a target for anticancer therapy	40
*	Telomerase Activity in Hematological Malignancies	
	Acute myeloid leukemia	43
	• Chronic myeloid leukemia	46
	• Acute lymphoid leukemia	48
	• Chronic lymphoid leukemia	50
	Myelodysplastic syndrome	53
	• Anti-telomerase therapy for leukemias	55
	• Telomerase activity in Hodgkin's-non Hodgkin's	
	lymphoma and other lymphoproliferative disorders	56

		Page
k	Telomerase Assays	
	• Telomere length as an indicator measure of telomerase	
	activity	61
	• Original telomere repeat amplification protocol (TRAP) .	. 63
	• TRAP with an internal standard	. 66
	• TRAP-SPA assay	. 67
	• Quantification method	
	• In situ PCR assay	. 69
	• TRAP-ELISA assay	. 70
	• Telomerase quantification by scintillation counting	. 71
	Polymerase chain reaction based radioactive telomerase	
	assay	
	• Combined electrophoretic-ELISA TRAP assay	. 72
	Cellular immunofluorescence based flowcytometry assay .	. 73
	• TRAP assay without shortening or lengthening of	•
	telomerase product	
	RTQ-TRAP system	
k-	Summary	
	References	
-	ARMADA WARNES TO THE TENTON OF THE TOTAL CONTROL OT	